- Trials with a EudraCT protocol (249)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
249 result(s) found for: Art therapy.
Displaying page 1 of 13.
EudraCT Number: 2016-000087-42 | Sponsor Protocol Number: TAISTR_2016 | Start Date*: 2016-05-11 |
Sponsor Name:University College Dublin | ||
Full Title: A multicentre, prospective, single arm, open-label 96 week observational trial of the tolerability, adherence and efficacy of a dolutegravir/abacavir/lamivudine single tablet regimen in HIV-1 antib... | ||
Medical condition: Human Immunodeficiency Virus (HIV) infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002281-12 | Sponsor Protocol Number: CT-BI-Vacc-4x-2012/1 | Start Date*: 2013-02-01 | |||||||||||
Sponsor Name:Bionor Immuno AS | |||||||||||||
Full Title: Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have... | |||||||||||||
Medical condition: Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017809-11 | Sponsor Protocol Number: 112673 | Start Date*: 2010-09-27 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase I/IIa randomized, observer-blind, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of the GSK Biologicals’ herpes zoster vaccine, gE/AS01B in comparison to pl... | |||||||||||||
Medical condition: Vaccination against herpes zoster (HZ) in adult HIV-infected subjects. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003040-25 | Sponsor Protocol Number: ANRS176 | Start Date*: 2022-09-01 | |||||||||||
Sponsor Name:Inserm-ANRS | |||||||||||||
Full Title: A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo during primary HIV-1 infection to study the impa... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000588-26 | Sponsor Protocol Number: MK-8591A-019 | Start Date*: 2020-03-02 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doraviri... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000251-24 | Sponsor Protocol Number: VIRECURE | Start Date*: 2015-06-10 |
Sponsor Name:Fundacio Privada Clinic per a la Recerca Biomedica | ||
Full Title: Impact of extremely early antiretroviral therapy to reduce VIral REservoir and induce functional CURE of HIV-1 infection. A pilot comparative study. | ||
Medical condition: HIV-1 infection | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006102-23 | Sponsor Protocol Number: ImmuneRaRe_RF-2019-12369708 | Start Date*: 2021-10-13 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Study of a novel combination of immunovirologic and genetic parameters in early-treated HIV-1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predicti... | |||||||||||||
Medical condition: HIV-1 positive subjects treated with effective antiretroviral therapy during the acute phase of HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002125-30 | Sponsor Protocol Number: AELIX-003 | Start Date*: 2019-05-09 | |||||||||||
Sponsor Name:AELIX Therapeutics | |||||||||||||
Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod (GS-9620), in early treated HIV-1 infection | |||||||||||||
Medical condition: Human immunodeficiency virus type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018097-64 | Sponsor Protocol Number: 114083 | Start Date*: 2010-03-03 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: Long-term follow-up of study participants from GlaxoSmithKline (GSK) Biologicals’-sponsored clinical trials evaluating Human Immunodeficiency Virus vaccine [F4co (p24-RT-Nef-p17)/AS01B vaccine] (73... | |||||||||||||
Medical condition: ART-treated and ART-naïve HIV-infected adults (ART: anti-retroviral therapy) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004819-37 | Sponsor Protocol Number: APART_2014 | Start Date*: 2015-04-16 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: A multi-centre, prospective, randomised trial of short course alendronate therapy or placebo combined with vitamin D and calcium to prevent loss of bone mineral density in antiretroviral-naïve, HIV... | |||||||||||||
Medical condition: Human immunodeficiency virus (HIV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DK (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004109-28 | Sponsor Protocol Number: DOLLARS | Start Date*: 2020-01-17 | |||||||||||
Sponsor Name:Daniel Podzamczer Palter | |||||||||||||
Full Title: HIV-1 RNA decay in semen and rectum and changes in HIV reservoir in rectal tissue in ART-naïve HIV+ men treated with dolutegravir plus lamivudine compared to Bictegravir/FTC/TAF (“DOLLARS study”) | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001419-21 | Sponsor Protocol Number: TPVAHC2012 | Start Date*: 2013-08-15 |
Sponsor Name:Universitätsklinikum Bonn | ||
Full Title: An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatiti... | ||
Medical condition: Acute Hepatitis C in HIV co-infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002114-38 | Sponsor Protocol Number: G9901441 | Start Date*: 2006-01-04 |
Sponsor Name:Medical Research Council Clinical Trials Unit | ||
Full Title: Ensayo randomizado para determinar el tratamiento óptimo de pacientes con infección por VIH en quienes la terapia con TARGA de primera y segunda línea ha fracasado | ||
Medical condition: human Immunodeficiency virus (HIV) infection. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002008-11 | Sponsor Protocol Number: IMC-M113V-103 | Start Date*: 2021-11-24 | |||||||||||
Sponsor Name:Immunocore Limited | |||||||||||||
Full Title: An open-label dose-escalation study evaluating the safety, pharmacokinetics and antiviral activity of IMC-M113V in HLA-A*02:01-positive subjects with chronic HIV infection who are virologically sup... | |||||||||||||
Medical condition: Chronic HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001159-37 | Sponsor Protocol Number: MK-5172-096 | Start Date*: 2017-05-02 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects with Chronic Hepatitis C Virus (HCV) G... | |||||||||||||
Medical condition: Hepatitis C Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005005-28 | Sponsor Protocol Number: ADENOFERT | Start Date*: 2022-11-08 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||
Full Title: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial featu... | |||||||||||||
Medical condition: Women with transvaginal ultrasound (TV-US)-based diagnosis of adenomyosis and women without adenomyosis but with similar baseline reproductive risks | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001288-26 | Sponsor Protocol Number: DASAHIVCURE | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:IDIBAPS | |||||||||||||
Full Title: Safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent HIV-1 infection | |||||||||||||
Medical condition: Recent HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001677-31 | Sponsor Protocol Number: AMB-001 | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in peop... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001476-37 | Sponsor Protocol Number: PENTA17 | Start Date*: 2015-12-16 | |||||||||||
Sponsor Name:Fondazione PENTA ONLUS | |||||||||||||
Full Title: SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ... | |||||||||||||
Medical condition: Paediatric HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000199-41 | Sponsor Protocol Number: GESIDA10918 | Start Date*: 2019-07-10 | |||||||||||
Sponsor Name:Fundación SEIMC-GESIDA | |||||||||||||
Full Title: A phase IV, multicenter, open and randomized study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in patients with type 1 HIV i... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
